Chapters

Transcript

Video

Once the importance of uncoupling the androstenedione and glucocorticoid axes was understood, what targeting strategies were employed in the CAHtalyst trial that would lead to novel targeting of CRF1 with crinecerfont for CAH?

Once the importance of uncoupling the androstenedione and glucocorticoid axes was understood, what targeting strategies were employed in the CAHtalyst trial that would lead to novel targeting of CRF1with crinecerfont for CAH?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Richard Auchus, MD, PhD

Richard Auchus, MD, PhD

Professor of Pharmacology and Internal Medicine
Division of Metabolism, Endocrinology, and Diabetes
University of Michigan School of Medicine
Ann Arbor, Michigan